search
Back to results

The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain

Primary Purpose

Nausea and Vomiting, Postoperative

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
dexamethasone
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nausea and Vomiting, Postoperative

Eligibility Criteria

3 Years - 7 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 3-7 years of age
  • tonsillectomy with or without adenoidectomy and tympanostomy tube placement

Exclusion Criteria:

  • Subjects receiving one week before surgery:

    •-antiemetics

  • steroids
  • anti-histaminic
  • psychoactive drugs

Sites / Locations

  • Children's Hospital of ColoradoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

IV Dexmethsone and oral placebo

Oral dexamethasone and IV placebo

Arm Description

Outcomes

Primary Outcome Measures

Incidence of post op nausea and vomiting
post-op nausea and vomiting as evidenced by vomiting and/or retching without expulsion of gastric content

Secondary Outcome Measures

pain scores and surgical re-exploration for bleeding
Pain as evidenced by a numeric pain scale 0-10, Faces, Legs, Arms, Crying, Consolability Scale (FLACC Scale), or Revised Faces Scale.12,13 . surgical re-exploration as evidenced by the return to O.R. for bleeding

Full Information

First Posted
September 18, 2020
Last Updated
January 17, 2023
Sponsor
University of Colorado, Denver
search

1. Study Identification

Unique Protocol Identification Number
NCT04563494
Brief Title
The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain
Official Title
The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, Pain, and Drug Cost in Children Undergoing Tonsillectomy: A Randomized Controlled Prospective Non-inferiority Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 23, 2020 (Actual)
Primary Completion Date
May 23, 2023 (Anticipated)
Study Completion Date
May 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The hypothesis being tested in this study is that perioperative oral administration of dexamethasone, when compared to intravenous (IV) administration, offers a similar reduction in postoperative nausea and vomiting (PONV), and reduction in postoperative pain in pediatric patients undergoing tonsillectomy with or without adenoidectomy and/or tympanostomy tube placement. The specific aim of this study is to demonstrate non-inferiority of oral dexamethasone when compared to IV dexamethasone, given that there is currently a severe, sudden, and world-wide shortage of IV dexamethasone given its recent use in treating patients with covid19 disease.
Detailed Description
written consent, patients will be randomized at the time of arrival to the preoperative care center on the day of surgery. One hundred twenty-six patients, 3 to 7 years of age undergoing tonsillectomy with or without adenoidectomy and tympanostomy tube placement, will be included in this study. Children who received antiemetics, steroids, anti-histaminic, or psychoactive drugs during the week before surgery will be excluded. Patients will be prospectively randomized to receive oral or IV dexamethasone 0.5 mg/kg (maximum dose 8 mg). Patients in the IV group will receive the dose once an IV is placed in the operating room. They will receive an oral placebo once consent is obtained on arrival to the preoperative center on the day of surgery. Patients in the oral group will receive their dose once consent is obtained on arrival to the preoperative center on the day of surgery. They will receive a placebo once the IV is placed in the operating room. Randomization will be via a computer-generated table of numbers. Study drugs will be marked only with a coded number label. The anesthesiologist, surgeon, patient, and family will be unaware of drug identity. All medication preparation and handling will be done by CHCO Investigational Drug Service. Patients will be fasted for solid foods for eight hours before surgery; clear liquids will be permitted until two hours before surgery. A standard anesthetic technique will be used. Premedication with oral acetaminophen 12.5-15 mg/kg will be given on arrival to the preoperative center. After obtaining consent study drug or placebo will be given at least 20 minutes before surgery. General anesthesia will be induced with sevoflurane and 60% nitrous oxide in oxygen via mask followed by insertion of an intravenous (IV) cannula. Dexamethasone or placebo will be given immediately following IV placement. Propofol 2 mg/kg and fentanyl 1 µg/kg will be given to facilitate intubation. Anesthesia will be maintained with a mixture of sevoflurane and air (FiO2 < 0.3All children will receive fentanyl 1-3 µg/kg (titrated to pain response in the operating room) and dexmedetomidine 0.5 µg/kg once surgery starts. All children will receive ondansetron 0.1 mg/kg (maximum dose 4 mg).All children will receive 20 mL/kg lactated Ringer's solution during surgery (maximum IV fluid 750 mL given short time of surgical procedure). Routine monitoring including heart rate (ECG), arterial oxygen saturation (SpO2), blood pressure, temperature and end-tidal CO2 will be used throughout surgery. Surgical technique will be standardized, and all patients will have their stomachs suctioned at the completion of surgery. Each subject will be assessed by nursing staff utilizing standard of care practices in the PACU and patients will stay in the PACU (phase one and two) for 4 hours after surgery. Postoperative nausea and vomiting (PONV) will be defined as vomiting and/or retching without expulsion of gastric content and will be treated with IV phenergan (0.25 mg/kg, maximum 25 mg) followed, if necessary, by IV diphenhydramine (1 mg/kg maximum 50 mg). Pain will be assessed using the numeric pain scale 0-10, Faces, Legs, Arms, Crying, Consolability Scale (FLACC Scale), or Revised Faces Scale.12,13 Pain scores > 5 will be treated with IV fentanyl 0.5 µg/kg that can be repeated every 5 minutes for pain when necessary.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nausea and Vomiting, Postoperative

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
126 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IV Dexmethsone and oral placebo
Arm Type
Active Comparator
Arm Title
Oral dexamethasone and IV placebo
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
dexamethasone
Intervention Description
Prevention of post op nausea and vomiting
Primary Outcome Measure Information:
Title
Incidence of post op nausea and vomiting
Description
post-op nausea and vomiting as evidenced by vomiting and/or retching without expulsion of gastric content
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
pain scores and surgical re-exploration for bleeding
Description
Pain as evidenced by a numeric pain scale 0-10, Faces, Legs, Arms, Crying, Consolability Scale (FLACC Scale), or Revised Faces Scale.12,13 . surgical re-exploration as evidenced by the return to O.R. for bleeding
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 3-7 years of age tonsillectomy with or without adenoidectomy and tympanostomy tube placement Exclusion Criteria: Subjects receiving one week before surgery: •-antiemetics steroids anti-histaminic psychoactive drugs
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa Brooks Peterson, MD
Phone
720-777-7068
Email
melissa.brooks@childrenscolorado.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melissa Brooks Peterson, MD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Melissa Brooks, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain

We'll reach out to this number within 24 hrs